The discovery of alterations in the levels of the CDK4/6 pathway in the context of breast cell proliferation and cancer [6,7] led to the discovery of new CDK4/6 inhibitors that have been dramatically modified for better BC therapy and the possibility for TNBC [8]. The gene discussed is CDK4; the disease is cancer.